Market Cap (In USD)
868.03 Million
Revenue (In USD)
-
Net Income (In USD)
-69.33 Million
Avg. Volume
241.18 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 14.35-36.37
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US04272N1028
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Zhengbin Yao Ph.D.
- Employee Count
- -
- Website
- https://www.arrivent.com
- Ipo Date
- 2024-01-26
- Details
- ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
More Stocks
-
ARRRFArdea Resources Limited
ARRRF
-
STG
-
JADE
-
PNRPentair plc
PNR
-
ACRFFAccor SA
ACRFF
-
6028
-
WPB
-
CBDG